The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Growth Hormone Reduces Fractures in Women with Osteoporosis

Growth Hormone Reduces Fractures in Women with Osteoporosis

September 4, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report.

You Might Also Like
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Hip Fractures Increasing in Older U.S. Women

“We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily Krantz, from Sodra Alvsborgs Hospital, Boras, Sweden, told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We were also surprised that quality of life (QoL) was constant throughout the entire follow-up time for all the treatment groups and that there was no difference between the patients and the control group,” she said.

In an earlier study of women with postmenopausal osteoporosis who received growth hormone for three years, bone mineral content improved and remained 14% higher one year after growth hormone was terminated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Krantz’s team now report bone data, fractures, and QoL in 80 of these women who were evaluated at the 10-year follow-up. All women received calcium and vitamin D and hormone replacement therapy.

In both growth hormone treatment groups (1.0 U and 2.5 U), serum IGF-1 increased during the trial and decreased to baseline levels when growth hormone was terminated after three years.

Bone mineral density and bone mineral content remained increased at four and five years in the growth hormone-treated groups, but by 10 years had decreased to baseline levels. They remained higher, however, in the 2.5 U growth hormone group than in the 1.0 U growth hormone group and in controls.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Just over half (56%) of the women had experienced fractures before inclusion in the study, but during the seven years after growth hormone was stopped, only 28% of women experienced fractures, according to the Aug. 27 online report in the Journal of Clinical Endocrinology & Metabolism.

In comparison, 8% of 120 population controls had suffered a fracture before, and 32% of population controls experienced fractures during the same study period.

Quality of life did not change significantly during growth hormone treatment, but it decreased with increasing age and was similar in patients and controls both at the start of the study and 10 years later.

“Today growth hormone is an expensive treatment, and although it is injected daily by the patients themselves, regular monitoring must be overseen by a specialist clinic, which is not in its favor when considering it in a practical clinical setting,” Dr. Krantz said.

“But osteoporosis is a severely undertreated disease and more must be done to discover at-risk patients and to tailor their treatment. I think that if growth hormone had existed in a long-acting preparation, so that it could be given once a week or once a month, that it could be of interest for this patient group,” she said.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Growth Hormone, Osteoporosis, postmenopause, Women

You Might Also Like:
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Hip Fractures Increasing in Older U.S. Women
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)